

Journal für  
**Urologie und Urogynäkologie**

Zeitschrift für Urologie und Urogynäkologie in Klinik und Praxis

**Should We Do Lymphadenectomy in  
Localised Kidney Cancer?**

Liedberg F

*Journal für Urologie und*

*Urogynäkologie 2010; 17 (Sonderheft*

*6) (Ausgabe für Österreich), 7-8*

Homepage:

[www.kup.at/urologie](http://www.kup.at/urologie)

Online-Datenbank mit  
Autoren- und Stichwortsuche

Indexed in Scopus

Member of the



[www.kup.at/urologie](http://www.kup.at/urologie)

Krause & Pachernegg GmbH · VERLAG für MEDIZIN und WIRTSCHAFT · A-3003 Gablitz

P. b. b. 022031116M, Verlagspostamt: 3002 Purkersdorf, Erscheinungsort: 3003 Gablitz

Unsere Räucherkegel fertigen wir aus den feinsten **Kräutern** und **Hölzern**, vermischt mit dem wohlriechenden **Harz** der **Schwarzföhre**, ihrem »Pech«. Vieles sammeln wir wild in den Wiesen und Wäldern unseres **Bio-Bauernhofes** am Fuß der Hohen Wand, manches bauen wir eigens an. Für unsere Räucherkegel verwenden wir reine **Holzkohle** aus traditioneller österreichischer Köhlerlei.

»Eure Räucherkegel sind einfach wunderbar.  
Bessere Räucherkegel als Eure sind mir nicht bekannt.«  
– Wolf-Dieter Storl

synthetische  
**OHNE**  
Zusätze

# Waldweihrauch

»Feines Räucherwerk  
aus dem *Schneeberg*«  
L A N D



[www.waldweihrauch.at](http://www.waldweihrauch.at)

# Should We Do Lymphadenectomy in Localised Kidney Cancer?



EU\*ACME

F. Liedberg

## ■ Introduction

Nodal involvement in renal carcinoma is described in 3.3–46 % of patients in the literature [1, 2]. Such a wide range of lymph node metastases depends mainly on selection of patients, but type of cohort investigated, i.e. autopsy series as compared to surgical series and extent of lymphadenectomy performed in surgical series, also have an impact on the prevalence of lymph node metastases. Also the continuous downward stage migration of the disease results in lower rates of lymph node metastases in series published in the modern era. The current lecture will try to answer the question „Should we do lymphadenectomy in localised renal carcinoma“, and will expand the answer somewhat beyond the current updated EAU-guidelines from April 2010 and the following statement:

## ■ Lymph Node Dissection

An extended or radical lymph node dissection does not appear to improve long-term survival following tumour nephrectomy. Thus, for staging purposes, the lymph node dissection can be limited to the hilar region. In patients with palpable of CT-detected enlarged lymph nodes, resection of the affected lymph nodes should be performed to obtain adequate staging information.

## ■ Localised Renal Carcinoma

In the new TNM-classification published 2009 some changes have been made as compared to the 2002 classification. See below:

### TNM 2009 Renal cancer

- Primary tumour T
- T1a Tumour  $\leq 4$  cm
- T1b Tumour  $> 4$  cm but  $\leq 7$  cm in greatest dimension
- T2a Tumour  $> 7$  cm but  $\leq 10$  cm in greatest dimension, limited to the kidney (localised disease)
- T2b Tumour  $> 10$  cm, limited to the kidney (localised disease)

- T3a Tumour grossly extends into renal vein or perirenal and/or sinus (peripelvic) fat but not beyond Gerota's fascia
- T3b Tumour grossly extends into vena cava below the diaphragm
- T3c Tumour grossly extends into vena cava above the diaphragm or invades the wall of vena cava
- T4 Tumour grossly invades beyond Gerota's fascia (including contiguous extension into the ipsilateral adrenal gland)

### Regional Lymph Nodes N

- N0
- N1 Metastases in single regional lymph node
- N2 Metastases in more than one regional lymph node

## ■ Renal Lymphatic Drainage

The lymphatic drainage of the retroperitoneum, and the kidneys in particular, is unpredictable. The initial anatomic description of retroperitoneal lymphatics by Parker [3] indicates a variable pattern, which has been further verified, among others, in an autopsy study by Johnsen [4]. Autopsies of 554 patients with clinically undetected renal carcinoma were identified. Of all patients, 80 had lymph node metastases, with only one out of 4 patients (25 %) with lymph node metastases restricted to the retroperitoneum as compared to lymph node metastasis outside the retroperitoneum. Isolated paracaval or paraaortic lymph node metastases without any other metastatic deposits were identified in only 5 subjects (0.9 % of all 554 patients).

## ■ Extent and Technique of Lymphadenectomy

The variability of the lymphatic drainage described above explains the disagreement about the ideal limits of lymph node dissection (LND) in renal carcinoma [5–7]. Limited as compared

to extended dissection results in understaging, especially on the right side, where interaortocaval lymph nodes are the primary lymphatic landing area. Frozen section examination (FSE) of intraoperatively detected or preoperatively described enlarged lymph nodes has recently been investigated in 114 patients. Only 32 % of patients with enlarged nodes had lymph node metastases, and when comparing FSE with lymph node status in a regional lymphadenectomy, 89 % sensitivity was reported, indicating that FSE maybe could be used to avoid unnecessary lymphadenectomy in patients with enlarged lymph nodes [8].

## ■ Imaging Techniques

In an often cited investigation by Studer, an incidence of only 42 % of histologically positive nodes was noticed in a series with preoperatively enlarged ( $> 1$  cm) nodes on abdominal CT [9]. There is currently no imaging method that can differentiate enlarged inflammatory nodes due to the tumour from metastatic ones. The value of FDG-PET/CT in renal carcinoma is at present not clear. Recently the first description of sentinel node imaging and surgery has been published, showing that the sentinel node concept is feasible also in renal carcinoma [10]. Possible applications of the sentinel node concept and clinical use of the method might be possible in the future.

### **Lymphadenectomy in:**

#### I. Patients with Localised Disease (T1–T2, N0, M0)

The lack of survival advantage in a randomized trial [11] together with the low incidence of positive nodes (3.3 %) in localised disease substantiates the recommendation to refrain from lymphadenectomy in these patients. The staging role of lymphadenectomy in these patients is also questionable in the absence of effective adjuvant therapies.

## II. Patients with Localised High-risk Disease (T3–T4, N0, M0)

In localised high-risk tumours the value of lymphadenectomy is currently unclear. The randomized EORTC trial 30881 included only 30 % of this patient category, and the study was with such a low incidence of lymph node metastases in this patient category (4 %) underpowered to conclude that survival without lymphadenectomy is equivalent to survival with lymphadenectomy. Risk factors for lymph node metastases such as clinical stage T3–T4, size > 10 cm, Fuhrman-grade III–IV, presence of sarcomatoid differentiation and histological necrosis have been identified in a multivariable analysis by Blute et al. [5]. However only tumour size and necrosis can be ascertained prior to surgery, and despite the fact that two or more of those risk factors was associated with a 15-fold higher incidence of regional lymph node metastases, such a stratification is not possible preoperatively with the identified risk factors. Tumour size and symptom classification has been identified in one study, and a nomogram was constructed [12], however the extent of lymphadenectomy was limited and not standardized in the study population. Thus, no firm recommendation can be made for these patients. However one institution states that „in the absence of any risk factors or incidental suspicious lymphadenopathy, probably any LND beyond the hilar nodes is not justified“ due to the low incidence of lymph node metastases [13].

## III. Patients with Regional Lymph Node Metastases without Distant Metastases

For patients in this category any evidence-based recommendations can be made. However, from retrospective studies it is a well-known fact that 1–10 % of patients have isolated retroperitoneal lymph node dissemination [4, 6], and that surgical cure is possible [6, 14]. In this patient category the challenge is to identify those patients preoperatively, as the

patient might benefit from an extended lymph node dissection in addition to remove enlarged lymph nodes. The limits of such an extended dissection in this group of patients is not known, however the interaortacaval nodes in right-sided tumours is probably of great importance [10]. Of course the extent of dissection is also affected by the patient's age, comorbidities and performance status.

## IV. Patients with Lymph Node Metastases and Distant Metastases

If cytoreductive nephrectomy is indicated in such a patient, the lymphadenectomy surgery could include only grossly enlarged nodes. Exstirpating lymph node metastases could possibly improve the effect of systemic therapies [15] as nodal disease shows a poor response to immunotherapy. No firm recommendation can however be made for these patients with regard to lymphadenectomy more than that an extended lymph node dissection is not indicated, as complications due to the lymph node surgery might prolong time to systemic palliative therapies.

## ■ Conclusions

In the era of increasing numbers of incidentally detected small renal carcinomas, lymphadenectomy in localised disease is seldom indicated. It is only beneficial in the absence of distant metastases, and under such circumstances possible as an extended dissection, where there might be a narrow therapeutic window for patients with local metastases only. However, there is clearly a lack of proper studies in these patients. The use of frozen section analysis of enlarged lymph nodes might be beneficial. In cytoreductive surgery before systemic therapies, exstirpation of grossly positive nodes could possibly be beneficial as part of the cytoreductive approach, but current knowledge is inadequate to give firm recommendations.

## Literature:

1. Blom JH, van Poppel H, Marechal JM, Jacqmin D, Sylvester R, Schroder FH, et al. Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. *Eur Urol* 1999; 36: 570–5.
2. Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. *J Urol* 2001; 166: 68–72.
3. Parker AE. Studies on the main posterior lymph channels of the abdomen and their connections with the lymphatics of the genitourinary system. *Am J Anat* 1935; 56: 409.
4. Johnsen JA, Hellsten S. Lymphatogenous spread of renal cell carcinoma: an autopsy study. *J Urol* 1997; 157: 450–3.
5. Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H. A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. *J Urol* 2004; 172: 465–9.
6. Giuliani L, Giberti C, Martorana G, Rovida S. Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. *J Urol* 1990; 143: 468–73.
7. Terrone C, Guercio S, De Luca S, Poggio M, Castelli E, Scoffone C, et al. The number of lymph nodes examined and staging accuracy in renal cell carcinoma. *BJU Int* 2003; 91: 37–40.
8. Ming X, Ningshu L, Hanzhong L, Zhongming H, Tonghua L. Value of frozen section analysis of enlarged lymph nodes during radical nephrectomy for renal cell carcinoma. *Urology* 2009; 74: 364–8.
9. Studer UE, Scherz S, Scheidegger J, Kraft R, Sonntag R, Ackermann D, et al. Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. *J Urol* 1990; 144: 243–5.
10. Bex A, Vermeeren L, de Windt G, Prevoo W, Horenblas S, Olmos RA. Feasibility of sentinel node detection in renal cell carcinoma: a pilot study. *Eur J Nucl Med Mol Imaging* 2010; 37: 1117–23.
11. Blom JH, van Poppel H, Marechal JM, Jacqmin D, Schroder FH, de Prijck L, et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. *Eur Urol* 2009; 55: 28–34.
12. Hutterer GC, Patard JJ, Perrotte P, Ionescu C, de La Taille A, Salomon L, et al. Patients with renal cell carcinoma nodal metastases can be accurately identified: external validation of a new nomogram. *Int J Cancer* 2007; 121: 2556–61.
13. Godoy G, O'Malley RL, Taneja SS. Lymph node dissection during the surgical treatment of renal cancer in the modern era. *Int Braz J Urol* 2008; 34: 132–42.
14. Canfield SE, Kamat AM, Sanchez-Ortiz RF, Detry M, Swanson DA, Wood CG. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1–2M0): the impact of aggressive surgical resection on patient outcome. *J Urol* 2006; 175: 864–9.
15. Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. *J Urol* 2003; 169: 2076–83.

## Correspondence:

Fredrik Liedberg, PhD, F.E.B.U.  
Section of Urology  
Växjö County Hospital  
SE-351 85 Växjö, Sweden  
E-Mail:  
fredrik.liedberg@ltkronoberg.se

# Mitteilungen aus der Redaktion

## Besuchen Sie unsere zeitschriftenübergreifende Datenbank

[Bilddatenbank](#)

[Artikeldatenbank](#)

[Fallberichte](#)

## e-Journal-Abo

Beziehen Sie die elektronischen Ausgaben dieser Zeitschrift hier.

Die Lieferung umfasst 4–5 Ausgaben pro Jahr zzgl. allfälliger Sonderhefte.

Unsere e-Journale stehen als PDF-Datei zur Verfügung und sind auf den meisten der marktüblichen e-Book-Readern, Tablets sowie auf iPad funktionsfähig.

[Bestellung e-Journal-Abo](#)

## Haftungsausschluss

Die in unseren Webseiten publizierten Informationen richten sich **ausschließlich an geprüfte und autorisierte medizinische Berufsgruppen** und entbinden nicht von der ärztlichen Sorgfaltspflicht sowie von einer ausführlichen Patientenaufklärung über therapeutische Optionen und deren Wirkungen bzw. Nebenwirkungen. Die entsprechenden Angaben werden von den Autoren mit der größten Sorgfalt recherchiert und zusammengestellt. Die angegebenen Dosierungen sind im Einzelfall anhand der Fachinformationen zu überprüfen. Weder die Autoren, noch die tragenden Gesellschaften noch der Verlag übernehmen irgendwelche Haftungsansprüche.

Bitte beachten Sie auch diese Seiten:

[Impressum](#)

[Disclaimers & Copyright](#)

[Datenschutzerklärung](#)